MolNFT v1 · #98862 · protein
Crystal structure analysis of O-acetylserine sulfhydrylase CYSK2 complexed with cystine from microcystis aeruginosa 7806
4LMB · Cysteine synthase: “Crystal structure analysis of O-acetylserine sulfhydrylase CYSK2 complexed with cystine from microcystis…”. X-ray diffraction, 2 ligands (CYS, PLP), 3 pockets (best druggability 0.74). MolNFT v1 #98862 on…
- PDB
- 4LMB
- Type
- protein
- Length
- 310 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Cysteine synthase
- EC
- 2.5.1.47
- UniProt
- A8YBP8
- Ligands
- CYS, PLP
- Pockets
- 3 · best druggability 0.74
Structure
x-ray diffraction · 1 distinct chain · 43% helix, 18% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Cysteine synthase (EC 2.5.1.47) | protein | 310 | 43% helix, 18% strand | A8YBP8 |
Ligands and binding sites
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 69 | 0.74 | 0.98 | 26 | PLP |
| 2 | 207 | 0.58 | 0.80 | 41 | CYS |
| 3 | 58 | 0.38 | 0.80 | 12 | empty |
Modifications
Observed in the structure: 1 cofactor (pyridoxal phosphate Schiff base).
Compared structures
- 4LMB · Crystal structure analysis of O-acetylserine sulfhydrylase CysK2 complexed with cystine… · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt A8YBP8
- Elsewhere: RCSB PDB 4LMB · PDBe 4LMB · UniProt A8YBP8
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.